David Coombs, head of multi-asset investing at Rathbones (LON:RAT) explains how his risk and return strategy has thrown up some unlikely winners during the coronavirus crisis. The portfolio was strong in healthcare ahead of the pandemic, he says, with stakes in med-tech group Abbot and pharma giant Roche, both of which have been very active in the fight against COVID-19. Another good performer has been Clorox, which prior to the pandemic had been a solid producer of cleaning wipes, he says, but has now seen its markets take off. “We are pragmatic in how we invest,” he told Proactive. “Currencies, commodities, bonds and equities, we go where we think the best returns are”.
Rathbones' risk and return strategy has paid off for multi-asset funds during crisis
Quick facts: Rathbone Brothers PLC
Price: 1680 GBX
Market Cap: £963.95 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE